Skip to content

Solve the Unsolved

Solve the Unsolved - StU

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55505
Enrollment
500
Registered
2019-06-24
Start date
2019-12-10
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inborn errors of metabolism and inherited metabolic disorder

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
No minimum to 99 Years

Inclusion criteria

Inclusion criteria: Patients (any age/gender/race) with an unexplained metabolic phenotype defined as: neurological symptoms and/or abnormalities on (physical) examination suggestive of an inborn error of metabolism (energy deficiency, intoxication type or storage type) AND / OR one or more of the following suggesting a deficient metabolic pathway or process: • abnormal metabolites in body fluids (CSF, urine, blood) • functional studies at a biochemical/cellular level which indicates a metabolic deficiency (e.g. respiratory chain complex analysis) • organ dysfunction (e.g. liver or kidney failure) • abnormalities on imaging (neuro-imaging (including spectroscopy); X-rays (dysostoses or other bone abnormalities); ultrasound (enlarged liver/spleen)) • a VUS (variant of unknown significance) in a gene involved in metabolism

Exclusion criteria

Exclusion criteria: after discussion by the Solve the Unsolved team the patient is suspected to have: - a genetic condition for which there is a simpler and more cost-effective test available for diagnosis - a complex genetic disorder (caused by a combination of multiple genes and/or environmental influences) - a condition that is thought to be caused by factors that are non-genetic, such as infection, injury or toxic exposure • he/she is unable to follow the study protocol (e.g. additional blood samples)

Design outcomes

Primary

MeasureTime frame
Identification of a genetic variant and alignment with its biochemical and phenotypical abnormalities.

Secondary

MeasureTime frame
Evaluating the diagnostic yield of combined WES/WGS and omics techniques.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)